Man Group
SPRO icon

Man Group’s Spero Therapeutics SPRO Stock Holding History

Man Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,481
Closed -$51.6K – 2184
2024
Q3 		$51.6K Sell
38,481
-34,988
-48% -$46.9K ﹤0.01% 1918
2024
Q2 		$95.5K Sell
73,469
-140,557
-66% -$212K ﹤0.01% 1968
2024
Q1 		$368K Buy
+214,026
New +$335K ﹤0.01% 1877
2022
Q4 		– Sell
-11,184
Closed -$22K – 2199
2022
Q3 		$22K Buy
+11,184
New +$11.1K ﹤0.01% 1934

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's SPRO Position: Q4 2024 in Review

Man Group sold out of Spero Therapeutics (SPRO) in Q4 2024, closing a stake of 38,481 shares — an estimated $51.6K sold.

Man Group first reported a position in SPRO in Q3 2022 and held it in 4 quarters. The position peaked at $368K in Q1 2024. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2024.

  • Man Group reported no remaining Spero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Man Group sold 38,481 Spero Therapeutics shares in Q4 2024, an estimated $51.6K.
  • Man Group first reported a position in Spero Therapeutics in Q3 2022 and held it in 4 quarters.
  • Man Group's Spero Therapeutics position peaked at $368K in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2024.

Based on Man Group's 13F filing for Q4 2024, filed 14 Feb 2025.